Fulton Breakefield Broenniman LLC Decreases Stake in Danaher Corporation $DHR

Fulton Breakefield Broenniman LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 6.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,948 shares of the conglomerate’s stock after selling 4,727 shares during the period. Fulton Breakefield Broenniman LLC’s holdings in Danaher were worth $13,273,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. WFA of San Diego LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $26,000. Howard Hughes Medical Institute purchased a new stake in Danaher in the 2nd quarter valued at $27,000. Red Tortoise LLC increased its stake in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares during the last quarter. Heartwood Wealth Advisors LLC acquired a new stake in shares of Danaher in the 3rd quarter worth $37,000. Finally, Ramirez Asset Management Inc. purchased a new position in shares of Danaher during the 2nd quarter worth $40,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.4%

Shares of NYSE DHR opened at $230.52 on Friday. The stock has a market cap of $162.83 billion, a P/E ratio of 47.53, a PEG ratio of 4.48 and a beta of 0.89. The business’s fifty day simple moving average is $222.66 and its 200-day simple moving average is $208.15. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.71 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is currently 26.39%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,248 shares of company stock worth $6,609,663 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on DHR. Morgan Stanley began coverage on Danaher in a report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target for the company. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. HSBC upped their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Evercore ISI lifted their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Twenty-one analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $248.25.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.